Results 141 to 150 of about 15,116 (246)
Re‐Emergent Postural Tremor Without Clinical Resting Tremor in Parkinson's Disease—A Case Report
Movement Disorders Clinical Practice, EarlyView.
Kevin R.E. van den Berg, Rick C. Helmich
wiley +1 more source
Effect of COMT and UGT1A Variants on Clinical Response to Opicapone in Parkinson's Disease
Movement Disorders Clinical Practice, EarlyView.Abstract Background Parkinson's disease (PD) is the second most common neurodegenerative disease. Symptomatic treatment is based on dopaminergic replacement. With disease progression, the initial benefit of levodopa becomes inconsistent, and motor complications emerge.
Elena Ojeda‐Lepe +15 more
wiley +1 more source
Breathe, Eat, Talk: Three Essential Ingredients to Quality‐of‐Life Outcomes in Movement Disorders
Movement Disorders Clinical Practice, EarlyView.Abstract Background Breathing, eating, and talking (BET) impairments are common yet frequently underrecognized features of movement disorders. Deficits in respiration, swallowing, voice, and speech may emerge early in the course of a disease, adversely affecting safety, participation, and quality of life.
John Dean +16 more
wiley +1 more source
, 2012 Objective: Recent studies showed high plasma homocysteine levels in patients treated with Levodopa for Parkinson’s disease (PD). Homocysteine, due to its exotoxic effect, might be the cause of polyneuropathy seen in PD.
Serkan Özben +3 more
core
Levodopa versus levodopa sparing in early parkinson’s disease: can we meet halfway?
Monotherapy is the recommended initial treatment for early Parkinson’s disease. The pharmacological options for initial treatment include dopaminergic agonists, monoamine oxidase B inhibitors, and levodopa formulations.
Amin Cervantes-Arriaga +7 more
core +1 more source
Exercise and Motor Complications in Parkinson's Disease: A Systematic Review and Meta‐Analysis
Movement Disorders Clinical Practice, EarlyView.Abstract Background Levodopa remains the most effective pharmacological treatment for Parkinson's disease (PD), but long‐term use commonly leads to motor complications such as levodopa‐induced dyskinesia (LID) and motor fluctuations, significantly contributing to disability. Exercise is well‐established for improving motor and non‐motor symptoms in PD;
Priscila Nóbrega‐Sousa +5 more
wiley +1 more source
Continuous Subcutaneous Foslevodopa/Foscarbidopa in Advanced Parkinson's Disease
Movement Disorders Clinical Practice, EarlyView.Abstract Background Continuous subcutaneous foslevodopa/foscarbidopa (LDp/CDp) provides 24‐h delivery of levodopa‐carbidopa prodrugs for advanced Parkinson's disease. Real‐world 1‐year European data remain limited. Objectives To characterize 1‐year changes in motor, non‐motor, autonomic, quality‐of‐life and sleep outcomes, and in concomitant therapy ...
Mario Hero +5 more
wiley +1 more source
Movement Disorders Clinical Practice, EarlyView.Abstract Background Lower urinary tract symptoms (LUTS) are among the most prevalent nonmotor complaints across the parkinsonian spectrum, yet they remain underutilized as diagnostic and management signals in neurology practice. Although prior reviews have characterized disease‐specific patterns of urinary dysfunction, and recent guidelines address ...
Saar Anis +3 more
wiley +1 more source
Dissociable Handwriting Domains in Parkinson's Disease?
Movement Disorders Clinical Practice, EarlyView.Abstract Background Handwriting abnormalities in Parkinson's disease (PD) extend beyond classical micrographia and may involve multiple graphomotor domains with distinct clinical and mechanistic correlates. Objectives To investigate whether distinct handwriting domains demonstrate dissociable relationships with differential diagnostic performance ...
Beyza Nur Cetin +3 more
wiley +1 more source